Stopping rivastigmine should be a planned decision with the prescriber, not an automatic response to worsening dementia. Ask whether it still provides meaningful benefit, causes harm, or warrants a closely monitored trial off treatment. Rivastigmine is an acetylcholinesterase inhibitor, a medicine that may ease dementia symptoms but does not stop the disease from progressing. NICE says clinicians should not stop this type of medicine solely because Alzheimer's disease has become severe in its dementia guideline.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What is rivastigmine expected to do?
- When might stopping be reasonable?
- What could happen after withdrawal?
- Has treatment already been interrupted?
- How should a stopping trial be planned?
What is rivastigmine expected to do?
The U.S. DailyMed label approves rivastigmine for mild-to-moderate Alzheimer's dementia and mild-to-moderate Parkinson's disease dementia. It treats symptoms rather than the underlying progression of dementia.
Worsening memory does not, by itself, show that the medicine has stopped helping. The useful comparison is what the person's cognition, daily functioning, or behavior might be with and without treatment. Ask the prescriber:.
- What benefit was rivastigmine originally intended to provide?
- Is there evidence that it still helps?
- Which changes could reflect dementia progression rather than treatment failure?
- How will we judge whether continuing is worthwhile?
When might stopping be reasonable?
Tolerability is an important reason to reassess treatment. DailyMed lists dose-related nausea, vomiting, diarrhea, reduced appetite, and weight loss. Vomiting and diarrhea can also cause potentially serious dehydration.
The 2018 Deprescribing.org and University of Sydney algorithm identifies other reasons to consider a stopping trial. These include unclear benefit, adverse effects, risky interactions, unresolved adherence problems, terminal illness unrelated to dementia, or a decision by the person, family, or carer. Bring specific information to the appointment:.
- Recent weight or appetite changes
- Vomiting, diarrhea, or difficulty keeping fluids down
- Missed oral doses or patch changes
- New medicines or suspected interactions
- Examples of changes in memory, behavior, or daily tasks
What could happen after withdrawal?
A 2021 Cochrane review examined seven randomized withdrawal trials involving 759 people. Stopping cholinesterase inhibitors may worsen cognition in the short term and probably worsens cognition and daily functioning at 12 months compared with continuing treatment according to the review. These findings do not mean that everyone should continue indefinitely.
Most of the evidence had low or very-low certainty, so the size and likelihood of harm remain uncertain. The evidence also has a narrow scope. Every participant had Alzheimer's dementia, and the review could not determine whether effects differed by disease severity. It therefore cannot establish what will happen after withdrawal in other dementia types, including Parkinson's disease dementia.
Has treatment already been interrupted?
Tell the prescriber exactly when the last dose or patch was used. Restarting after an interruption is not always the same as taking the next scheduled dose. For oral rivastigmine interrupted for more than three days, the label directs restarting at 1.5 mg twice daily and titrating again.
Resuming the former dose without guidance has been associated with severe vomiting and one reported esophageal rupture in the DailyMed prescribing information. For a patch interrupted for more than three days, the label directs restarting at 4.6 mg per 24 hours and titrating again in the patch prescribing information. Ask before replacing the patch at the previous strength.
How should a stopping trial be planned?
A stopping trial needs a shared plan. The prescriber should explain how treatment will change, how long observation will continue, and whom to contact if symptoms worsen.
Before the change, record the person's usual abilities and symptoms. Focus on concrete measures such as conversation, dressing, eating, mobility, agitation, sleep, and participation in familiar activities. Agree on these questions before starting:.
- Which cognitive, functional, or behavioral changes will be monitored?
- Who will record them, and how often?
- When will the prescriber review the results?
- What degree of decline would prompt reconsideration?
- If treatment must restart, what dose or patch strength is safe after the interruption?
